Vistagen therapeutics stock.

As of February 7, 2023, the Company had 219,326,526 shares of common stock outstanding, which reflects the issuance of approximately 12.4 million unregistered shares of common stock associated with the Pherin Pharmaceuticals transaction. Conference Call. ... VISTAGEN THERAPEUTICS, INC.Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those …Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and …Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...

Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 30, 2022-- Vistagen, (NASDAQ: …Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.VTGN has an Altman Z-Score of -5.47 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for VistaGen Therapeutics, Inc. (VTGN) stock, including valuation metrics, financial numbers, share information and more.0.72. +0.045. +6.6667%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...

In addition, VistaGen Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...In addition, VistaGen Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ... Aug 5, 2021. 2. Vistagen Therapeutics Inc - VTGN Based on 4 Wall Street analysts offering 12-month price targets for VistaGen Therapeutics in the last 3 months, the average …Sep 29, 2023 · Learn more about whether Vistagen Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. Latest Vistagen Therapeutics Inc Stock News

Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.As of June 22, 2022, the Company had 206,640,955 shares of common stock outstanding. Conference Call VistaGen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update and discuss its financial results for its fiscal year 2022 ended March 31, 2022 .Get the latest information on VistaGen Therapeutics Inc (VTGN), a biotechnology company developing gene therapies for neurological disorders. See the stock price, quote, chart, …H Snodgrass VTGN stock SEC Form 4 insiders trading. H has made over 3 trades of the VistaGen Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of VTGN stock worth $10,238 on 17 August 2021.. The largest trade he's ever made was buying 15,000 units of VistaGen …On August 10, VistaGen Therapeutics will report earnings from Q1. Analysts predict losses per share of $0.860. Watch VistaGen Therapeutics stock price move in real-time ahead here.

Nov 30, 2023 · The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...

Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the …On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ...VistaGen Therapeutics on Monday posted positive topline data from the Phase III PALISADE-2 trial, showing that its investigational nasal spray fasedienol met its primary endpoint, strongly easing distress among patients with social anxiety disorder. The market reacted enthusiastically to the news, sending VistaGen’s stock soaring around …Nov 30, 2023 · 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price. 1.34. +0.02. +1.52%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price.

3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and …

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PM

Aug. 8, 2023, 12:10 PM. There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VistaGen Therapeutics ( VTGN – Research Report ), Madrigal ...Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... Get the latest information on VistaGen Therapeutics Inc (VTGN), a biotechnology company developing gene therapies for neurological disorders. See the stock price, quote, chart, …VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript. Get the latest Vistagen Therapeutics, Inc. (VTGN) stock news and headlines to help you in your trading and investing ... VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023. 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents ...Analyst Recommendations on Vistagen Therapeutics, Inc. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. 2022. MT. William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform. 2022.Vistagen Therapeutics, Inc. 3.6900-0.0300 ... Plenty of stocks have been left behind and many carry outsize yields of 6% or more—including a total of about 40 in the S&P 500 and S&P MidCap 400 ...VistaGen Therapeutics (NASDAQ: VTGN) is a name you should know when it comes to cheap stocks. The company focuses on developing next-generation therapies for central nervous system (CNS) disorders and other therapeutic areas. While most penny stocks are speculative and risky, VistaGen has several specialties that make it worth …Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety ...Nov 30, 2023 · The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...

3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ..."Phase 3 topline results due in 2H 2023." This is one of three upcoming announcements for the company. VistaGen Therapeutics inched up $0.0018 (+1.29%) to $0.14 ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.Stifel Nicolaus initiated coverage on shares of Vistagen Therapeutics ( NASDAQ:VTGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $12.00 price target on the stock. Separately, Maxim Group reiterated a buy rating and issued a $30.00 price target on shares of …Instagram:https://instagram. otcmkts wrlgfvanguard ftseexito bogotahow do i invest in lithium Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors 1800flowers stocklmnl Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. is tradovate free In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $12.00. Jason McCarthy’s Buy ...See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...